News
TGD001 receives Orphan Drug Designation in Europe
July 29, 2024
TargED Biopharmaceuticals is thrilled to announce that the European Medicines Agency has granted Orphan Drug Designation for their innovative therapy, TGD001! This first-in-class thrombolytic is set to make a significant impact in the treatment of Thrombotic Thrombocytopenic Purpura (TTP).
Download the full article